Oncology PracticeNivolumab boosts overall survival in HCCOctober 14, 2019GastroenterologyImmuno-oncologyGastrointestinal Cancer
Hematology NewsWhat is the optimal duration of maintenance in myeloma?October 8, 2019Multiple MyelomaLymphoma & Plasma Cell Disorders
Oncology PracticeAtezolizumab plus chemo gives slight PFS edge in mUCOctober 8, 2019Genitourinary CancerImmuno-oncology
Oncology PracticePRIMA study: Niraparib maintenance improves PFS in advanced OCOctober 8, 2019Gynecologic Cancer
Oncology PracticeRibociclib/fulvestrant boosts survival in advanced breast cancerOctober 4, 2019Breast Cancer
Hematology NewsTargeted agents vs. chemoimmunotherapy as first-line treatment of CLLOctober 3, 2019CLLLymphoma & Plasma Cell DisordersB Cell LymphomaLeukemia, Myelodysplasia, Transplantation
Oncology PracticemIDH1 inhibitor ivosidenib improves progression-free survival in advanced cholangiocarcinomaOctober 1, 2019GastroenterologyRare DiseasesGastrointestinal Cancer
Hematology NewsDecoding biosimilar approvalsOctober 1, 2019B Cell LymphomaLymphoma & Plasma Cell Disorders
Hematology NewsStudy finds no standard for treatment discontinuation in myelomaOctober 1, 2019Multiple MyelomaLymphoma & Plasma Cell Disorders
Oncology PracticeMONARCH 2: Abemaciclib plus fulvestrant improves overall survivalOctober 1, 2019Breast Cancer
Hematology NewsImmunotherapies under investigation in newly diagnosed B-ALLOctober 1, 2019ALLLeukemia, Myelodysplasia, TransplantationImmunotherapyImmuno-oncologyCellular Therapy
Oncology PracticeImmunotherapy duo extends survival in first line for advanced NSCLCSeptember 29, 2019Lung CancerLung Cancer
Oncology PracticePAOLA-1/ENGOT-ov25 trial: PARP inhibitor for maintenance improves PFS in advanced ovarian cancerSeptember 29, 2019Gynecologic Cancer
Oncology PracticeCardiotoxicity after checkpoint inhibitor treatment seen early, linked to elevated biomarkersSeptember 29, 2019Lung Cancer
